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bstract: 
Theranostic, has positioned itself  as a 
promising  technique to fight cancer, 
especially when using radioactive isotopes, 
where it has demonstrated good efficiency in human 
cancer treatment and in the animal phase study. The 
technique basically consists in using a chemical 
element with several radioactive isotopes. One 
diagnostic (gamma or β+ emitter) and another isotope 
of the same therapeutic element (alpha, β+, β- or 
Auger electrons). These isotopes must be linked to a 
vector molecule expressed by the tumor cells of the 
corresponding type of cancer. Radioisotopes can also 
be encapsulated in nanoparticles. 
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1. INTRODUCTION 
The treatment of cancer with radiation therapy begins 
at the beginning of the XX century with the early works 
of Marie Curie [1] and the treatment of skin cancer. At 
present times, external radiation (external 
radiotherapy-RTE) and interstitial or intracavitary 
radiation (brachytherapy-BQT) of tumours is used in 
60% of different types of cancer, with results around 
60% of cure with acceptable quality of life [2]. 
However, both RTE and BQT have the disadvantage 
that dose delivered to healthy tissues is relatively high 
(larger in the first one), so that the maximum dose is 
conditioned by the damage caused to the healthy 
tissues surrounding the tumour. Techniques that 
radiate as little as possible to healthy tissues are being 
permanently sought, such as IMRT (intensity 
modulated radiotherapy), proton therapy, VMAT 
(volumetric arc-therapy), etc. All of them are RTE-type 
techniques [3]. 
At the end of last century new treatment methods 
were developed consisting of cell therapies, among 
which being the most notorious  the theranostic 
technique using radioactive isotopes. 
 
2. MATERIALS AND METHODS 
  
Figure 1. Left Simple outline of the theranostic. Right SPECT with 
radiosiotopes (Muller, C., et all . Journal of Nuclear Medicine 
55(10):1658–64). 
The theranostic with radioisotopes makes use of a 
chemical element that has at least two radioactive 
isotopes. One of them is a gamma or positron emitter 
used to obtain the image of the tumour. The other is 
an alpha, beta or Auger electron emitter, delivering the 
required dose for therapy. 
The most important feature of the theranostic 
approach is that the technique produces minimum 
damage to the cells of healthy tissues located in the 
vicinity of the tumour:  it is thus a targeted-cell therapy. 
In order to distinguish between cancer cells and 
healthy tissue, vectors (ligand molecules) must be 
made available, to which the radioisotope is attached 
(Figure 1, Left). For example, in ovarian cancer it is 
known that it primarily expresses folate [4]. If a 
radioactive isotope is attached to the folate molecule, 
by injecting this radiopharmaceutical into the 
bloodstream, the vast majority of this 
radiopharmaceutical will be absorbed by the ovarian 
cancer cells. With the diagnostic radioisotope we will 
verify, by means of the Nuclear Medicine imaging 
system (SPECT-CT or PET) and once assured of this, the 
therapeutic isotope that will cause the death or 
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apoptosis of the tumor cells is introduced (Figure 1, 
right) . 
A recently emerging theranostic technology is based on 
the use of nanoparticles to encapsulate the 
radioisotope and dope the nanoparticles with ligand 
molecules expressed by the various types of tumors 
[5]. 
 
3. RESULTS AND DISCUSSION 
Some radioisotopes such as 131I have been widely used 
for some time in therapy, both for thyroid cancer and 
as a therapeutic measure for hyperthyroidism. 
Other radioactive isotopes under development for 
targeting bone cancer are 89Sr, 153Sm, 177Lu and 
188/186Re. Somatostatin receptor peptides labeled with 
90Y or 177Lu showed effectiveness for the treatment of 
neuroendocrine tumors in ongoing clinical trials, 
though they are not yet approved for clinical usage. 
Some clinical trials recall the use of 213Bi in acute 
myelogenous leukemia (AML), melanoma, and 
lymphoma; 225Ac for AML; 223Ra for bone cancer, and 
211At for glioblastoma and ovarian cancer [6]. 
 
Other new radioisotopes such as Terbium 
(149,152,155,161Tb) are being positioned in the market as 
elements of great destruction capability of specific 
tumor cells. However, there are difficulties in obtaining 
these isotopes. Only some for some few cases such as 
Xofigo©, the radiopharmaceuticals are not yet 
produced commercially and only available in some 
research centers, which makes difficult to develop this 
technique in hospitals not included in the clinical trials. 
On the other hand, there is still an important question 
to clarify: what is the most adequate prescription dose 
for each type of tumor? It is necessary to develop 
clinical dosimetry techniques, similarly as it is done in 
the RTE or BQT. So far almost all treatments are carried 
out considering the injected activity, in mCi, but not the 
dose received by the tumor, in Gy. 
4. CONCLUSIONS 
The theranostic method presents many appealing 
advantages over RTE or BQT since it is a local treatment 
at the cellular level whereby, if the appropriate ligand 
molecule can be obtained to produce the 
corresponding radiopharmaceutical, the tumor cells 
can be destroyed or killed by apoptosis, and the 
damage of healthy tissues is minimal. If the cancer cells 
are treated with ⍺ radiation, the overall penetration in 
the tissues is only of a few hundred microns, and of a 
few millimiters when using β- radiation, therefore 
minimizing the damage over healthy tissues. On the 
other hand, the imaging technique allows to monitor 
and control the dose deposited over the tumour, its 
evolution and the area to be treated, thus offering an 
absolutely personalized treatment. The big challenge is 
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